scholarly journals Erratum to: PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Ji-Youn Han ◽  
Jae-Jin Choi ◽  
Jin Young Kim ◽  
You Lim Han ◽  
Geon Kook Lee
Keyword(s):  
Lung Cancer ◽  
Melting Curve ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Curve Analysis ◽  
Melting Curve Analysis ◽  
Small Cell Lung ◽  
Kras Mutations ◽  
Fluorescence Melting Curve Analysis ◽  
Tumor Dna

scholarly journals Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yongliang Zhang ◽  
Yu Yao ◽  
Yaping Xu ◽  
Lifeng Li ◽  
Yan Gong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Chinese Patients ◽  
Plasma Samples ◽  
Small Cell Lung ◽  
Pan Cancer ◽  
Tumor Dna

AbstractCirculating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient’s genomic landscape and actionable information. Here, we design a ctDNA-based study of over 10,000 pan-cancer Chinese patients. Using parallel sequencing between plasma and white blood cells, 14% of plasma cell-free DNA samples contain clonal hematopoiesis (CH) variants, for which detectability increases with age. After eliminating CH variants, ctDNA is detected in 73.5% of plasma samples, with small cell lung cancer (91.1%) and prostate cancer (87.9%) showing the highest detectability. The landscape of putative driver genes revealed by ctDNA profiling is similar to that in a tissue-based database (R2 = 0.87, p < 0.001) but also shows some discrepancies, such as higher EGFR (44.8% versus 25.2%) and lower KRAS (6.8% versus 27.2%) frequencies in non-small cell lung cancer, and a higher TP53 frequency in hepatocellular carcinoma (53.1% versus 28.6%). Up to 41.2% of plasma samples harbor drug-sensitive alterations. These findings may be helpful for identifying therapeutic targets and combined treatment strategies.

scholarly journals Analysis of Circulating Tumor DNA Kinetics during Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer

2018 ◽  
Vol 102 (3) ◽  
pp. e676
Author(s):  
E.L. Chen ◽  
A.A. Chaudhuri ◽  
B.Y. Nabet ◽  
J.J. Chabon ◽  
D.J. Merriott ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tumor Dna ◽  
Stereotactic Ablative Radiation Therapy

scholarly journals Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Jingying Nong ◽  
Yuhua Gong ◽  
Yanfang Guan ◽  
Xin Yi ◽  
Yuting Yi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Analysis ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Genomic Evolution ◽  
Small Cell Lung ◽  
Tumor Dna

Circulating Tumor DNA Minimal Residual Disease Detection of Non–Small-Cell Lung Cancer Treated With Curative Intent

2022 ◽  
Author(s):  
Bruna Pellini ◽  
Aadel A. Chaudhuri
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Residual Disease ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Post Treatment ◽  
Small Cell Lung ◽  
Curative Intent ◽  
Tumor Dna ◽  
Minimal Residual

Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC). Multiple groups have shown the ability to detect MRD following curative-intent NSCLC treatment using next-generation sequencing–based assays of plasma cell-free DNA. These studies have been modest in size, largely retrospective, and without thorough prospective clinical validation. Still, when restricting measurement to the first post-treatment timepoint to assess the clinical performance of ctDNA MRD detection, they have demonstrated sensitivity for predicting disease relapse ranging between 36% and 100%, and specificity ranging between 71% and 100%. When considering all post-treatment follow-up timepoints (surveillance), including those beyond the initial post-treatment measurement, these assays' performances improve with sensitivity and specificity for identifying relapse ranging from 82% to 100% and 70% to 100%, respectively. In this manuscript, we review the evidence available to date regarding ctDNA MRD detection in patients with NSCLC undergoing curative-intent treatment and the ongoing prospective studies involving ctDNA MRD detection in this patient population.

scholarly journals Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment

Lung Cancer ◽  
2020 ◽  
Vol 145 ◽  
pp. 173-180 ◽  
Author(s):  
Jamie J. Beagan ◽  
Sander Bach ◽  
Robert A. van Boerdonk ◽  
Erik van Dijk ◽  
Erik Thunnissen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Analysis ◽  
Kinase Inhibitor ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Egfr Mutant ◽  
Tumor Dna ◽  
Inhibitor Treatment

scholarly journals Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer

2020 ◽  
Vol 9 (5) ◽  
pp. 1873-1884
Author(s):  
Gloria Y. F. Ho ◽  
Tao Wang ◽  
Hoi-Hin Kwok ◽  
Rehana Rasul ◽  
Rita Peila ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Circulating Tumor Dna ◽  
Tumor Burden ◽  
Small Cell ◽  
Gene Panel ◽  
Molecular Characteristics ◽  
Small Cell Lung ◽  
Tumor Dna

Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer

Lung Cancer ◽  
2019 ◽  
Vol 134 ◽  
pp. 108-116 ◽  
Author(s):  
Bin Zhang ◽  
Xueliang Niu ◽  
Qiang Zhang ◽  
Chunli Wang ◽  
Bo Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Dna Detection ◽  
Circulating Tumor Dna ◽  
Small Cell ◽  
Small Cell Lung ◽  
Histologic Types ◽  
Tumor Dna
Sign in / Sign up

Export Citation Format

Share Document